PHR Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -5.83% compared to Phreesia's net margin of -1.05%. Phreesia's return on equity of -22.95% beat Astrana Health's return on equity of 9.13%.

Phreesia has a consensus price target of $32.31, signalling upside risk potential of 26.9%. On the other hand Astrana Health has an analysts' consensus of $50.4546 which suggests that it could grow by 68.97%. Given that Astrana Health has higher upside potential than Phreesia, analysts believe Astrana Health is more attractive than Phreesia.

Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.424%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phreesia quarterly revenues are $109.7M, which are smaller than Astrana Health quarterly revenues of $665.2M. Phreesia's net income of -$6.4M is higher than Astrana Health's net income of -$7M. Notably, Phreesia's price-to-earnings ratio is -- while Astrana Health's PE ratio is 33.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.49x versus 0.70x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -5.83% compared to Phreesia's net margin of 13.04%. Phreesia's return on equity of -22.95% beat Cryo-Cell International's return on equity of --.

Phreesia has a consensus price target of $32.31, signalling upside risk potential of 26.9%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 31.99%. Given that Cryo-Cell International has higher upside potential than Phreesia, analysts believe Cryo-Cell International is more attractive than Phreesia.

Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.282%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 7.76% to investors and pays a quarterly dividend of $0.25 per share. Phreesia pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Phreesia quarterly revenues are $109.7M, which are larger than Cryo-Cell International quarterly revenues of $8.1M. Phreesia's net income of -$6.4M is lower than Cryo-Cell International's net income of $1.1M. Notably, Phreesia's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 135.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.49x versus 1.65x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of -5.83% compared to Phreesia's net margin of -3.53%. Phreesia's return on equity of -22.95% beat Evolent Health's return on equity of -5.92%.

Phreesia has a consensus price target of $32.31, signalling upside risk potential of 26.9%. On the other hand Evolent Health has an analysts' consensus of $15.33 which suggests that it could grow by 58.4%. Given that Evolent Health has higher upside potential than Phreesia, analysts believe Evolent Health is more attractive than Phreesia.

Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.872%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Evolent Health pays out -32.59% of its earnings as a dividend.

Phreesia quarterly revenues are $109.7M, which are smaller than Evolent Health quarterly revenues of $646.5M. Phreesia's net income of -$6.4M is higher than Evolent Health's net income of -$22.8M. Notably, Phreesia's price-to-earnings ratio is -- while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.49x versus 0.43x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -5.83% compared to Phreesia's net margin of 5.16%. Phreesia's return on equity of -22.95% beat Omnicell's return on equity of 1.04%.

Phreesia has a consensus price target of $32.31, signalling upside risk potential of 26.9%. On the other hand Omnicell has an analysts' consensus of $51.00 which suggests that it could grow by 44.64%. Given that Omnicell has higher upside potential than Phreesia, analysts believe Omnicell is more attractive than Phreesia.

Phreesia has a beta of 0.823, which suggesting that the stock is 17.706% less volatile than S&P 500. In comparison Omnicell has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.543%.

Phreesia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phreesia pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Phreesia quarterly revenues are $109.7M, which are smaller than Omnicell quarterly revenues of $306.9M. Phreesia's net income of -$6.4M is lower than Omnicell's net income of $15.8M. Notably, Phreesia's price-to-earnings ratio is -- while Omnicell's PE ratio is 130.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phreesia is 3.49x versus 1.47x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.